Johnson & Johnson has announced that it is separating its company’s consumer health business, creating a new publicly traded company. The company is targeting the completion of the planned separation in 18-24 months.
According to the company, the planned separation would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.
The new consumer health company would be a global consumer health company, featuring brands such as Neutrogena, Aveeno, Tylenol, Listerine, Johnson’s, and Band-Aid and leading positions in self-care (OTC), skin health and essential health, which include baby care, feminine care, wound care and oral health.
The updated Johnson & Johnson would continue to build on its offering of health care R&D and innovation with its portfolio entailing pharmaceutical and medical device capabilities focused on advancing standard care.
By Jacquelyn Schlabach – Nov 12th, 2021
Beatrice Wihlander 11 June 2025 Givaudan is showcasing its fragrance technologies, which are underscored by…
After over 10 years of testing sunscreen products, at Zurko Research we are proud to…
Mack Degueurin 22 April 2025 The wearable device analyzes the tiny changes in physical responses…